Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.57

-0.8%

Nov 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (1349)	6/27/2002 1:51:48 AM
From: aknahow	of 1475

The FDA position and data presented show that BGEN data did not support its' most strident claim to 9 months mean duration. I thought that approval of Amevive would turn the biotech market around. Now it remains to be seen what BGEN what questions require a complete response. Given the fact that what one now is able to see about Amevive vs what was claimed by BGEN creates doubt that the whole process is as simple as BGEN claims. No objections to any of the questions asked. My shock is that the Amevive seen in the document appears quite different than the Amevive investors were led to believe existed. Institutional investors will be going over the document and making their decisions. A large long term post market trial is a given but how long will it take the FDA and BGEN to agree on the design of this trial? Institutional investors will be going over the document and making their decisions. For individual investors the question may well become how many times can management's say anything to preserve their necks while the facts are known only to insiders until it is too late.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next